Skip to content

15% off your first order

PerformanceEarly clinical

AOD-9604

Last reviewed September 26, 2026

AOD 9604 is a synthetic peptide derived from the C-terminal fragment of human growth hormone, isolated for research into fat metabolism without the broader activity of the full hormone.

Mechanism of action

Research describes AOD 9604 as retaining the lipolytic-associated portion of the growth hormone molecule while lacking the regions tied to its effects on growth and glucose handling.

  • GH FragmentStudied as a specific fragment of growth hormone, isolated to narrow the research focus to metabolic pathways.
  • Lipid MetabolismExplored in research on fat metabolism signaling without the systemic profile of the full hormone.
Route studied
Subcutaneous
Research status
Early clinical

AOD-9604 has been reviewed as an investigational metabolic and anti-obesity compound in clinical development, but no late-stage trial results or regulatory approvals are documented here.

RESEARCH

What the research covers

What research examines

  • Fat metabolism and lipolysis signaling
  • Investigational anti-obesity research
  • Metabolic activity separated from full growth hormone effects
  • Detection and in vitro metabolism in anti-doping science
  • Interaction with growth hormone isoform immunoassays

Reported effects in studies

  • Human safety data are limited
  • Adverse events are not summarized in the cited studies
  • Described as lacking the growth hormone regions tied to growth and glucose handling
  • Reported not to affect IGF-1 in its research profile
  • Studied in anti-doping detection contexts
STUDIED RANGE

What research protocols have used

Research protocols have used 250–500 mcg per administration, once daily (morning, fasted), in 12-week blocks with 4 weeks off.

For research use only. These figures summarize published research protocols. They are not instructions or medical advice.

Every CoreX order ships with a per-lot protocol guide.

Open the reconstitution calculator
STACKS WITH

Researched alongside

GLP-3RGLP-3R is studied as a triple agonist at the GLP-1, GIP, and glucagon receptors. Research examines whether engaging all three affects metabolic regulation differently to dual or single agonists.Read profileTirzepatideTirzepatide is studied as a dual agonist at the GIP and GLP-1 receptors. Research examines whether combining the two incretin pathways differs from GLP-1 agonism alone.Read profile5-Amino-1MQ5-Amino-1MQ is a small molecule studied as an inhibitor of nicotinamide N-methyltransferase, an enzyme associated with fat-cell metabolism and cellular NAD+ availability.Read profileTesamorelinTesamorelin is a stabilized growth-hormone-releasing hormone analog. Research examines its role in endogenous GHRH signaling and its association with visceral adipose tissue.Read profile
STUDIES

Cited research

  1. AOD-9604 Metabolic.

    Current opinion in investigational drugs (London, England : 2000) · 2004 · Review · PubMed 15134286

  2. AOD-9604 does not influence the WADA hGH isoform immunoassay.

    Drug testing and analysis · 2013 · PubMed 24124033

  3. Detection and in vitro metabolism of AOD9604.

    Drug testing and analysis · 2015 · PubMed 25208511

FAQ

Questions about AOD-9604

AOD-9604 is a synthetic peptide derived from the C-terminal fragment of human growth hormone. It was isolated to support research into fat metabolism without the broader activity of the full hormone. It is often described as a metabolic fragment, and it has been reviewed in the literature as an investigational compound in metabolic and obesity-related research. CoreX supplies AOD-9604 for laboratory research use only.

Research describes AOD-9604 as retaining the portion of the growth hormone molecule associated with lipolysis while lacking the regions tied to growth and glucose handling. This narrower structure lets researchers study fat metabolism signaling without the systemic profile of the full hormone. Its research profile is characterized as direct lipolysis with no IGF-1 impact, which distinguishes it from full-length growth hormone in experimental work.

AOD-9604 has been studied mainly for its role in lipid metabolism and as an investigational anti-obesity compound, with reviews covering its metabolic profile. Separate analytical work has examined how it can be detected, how it is metabolized in vitro, and whether it interferes with the anti-doping growth hormone isoform immunoassay. One study reported that AOD-9604 does not influence that immunoassay.

Human safety data for AOD-9604 are limited, and adverse events are not summarized in the cited studies. Its research profile is described as lacking the growth hormone regions associated with growth and glucose handling, and as having no impact on IGF-1. Because published safety information is sparse, conclusions about tolerability should be drawn cautiously and only from primary study reports.

Research protocols have used 250 to 500 mcg per administration, once daily in the morning under fasted conditions, delivered subcutaneously. These protocols have run in 12-week blocks followed by 4 weeks off. These figures describe published or reported research designs only and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference.

Ask about AOD-9604

Our research assistant answers questions about the science, the studied ranges, and our products. It can be wrong, and it does not give medical advice.

Ask the assistant
FROM COREX

AOD-9604 at CoreX

Every batch is independently tested for identity and purity, and the certificate of analysis is tied to the lot number on your label.

AOD9604 5mg
AOD9604 5mg

Performance

$89.00